Last reviewed · How we verify
Placebo (double-blind)
Placebo produces no pharmacological effect and serves as a control comparator in clinical trials to measure the true efficacy of an investigational drug.
At a glance
| Generic name | Placebo (double-blind) |
|---|---|
| Also known as | Placebo |
| Sponsor | University of Rochester |
| Modality | Small molecule |
| Phase | Phase 3 |
Mechanism of action
Placebo is an inert substance administered in double-blind trials where neither the patient nor the investigator knows whether the subject is receiving active drug or placebo. Any clinical benefit observed in the placebo group is attributed to the placebo effect (psychological and contextual factors), allowing researchers to isolate the true pharmacological efficacy of the test drug by comparing outcomes between placebo and active treatment arms.
Approved indications
Common side effects
Key clinical trials
- Safety and Efficacy of L. Lactis CKDB001 in Subjects With Early Alzheimer's Disease (NA)
- A Study to Test Whether Nerandomilast Helps People With Lungfibrosis Related to Rheumatic Diseases (PHASE3)
- Safety, Tolerability, Pharmacokinetic and Pharmacodynamic of IY-828026 in Healthy Volunteers (PHASE1)
- A Study to Evaluate Mazdutide Compared With Placebo in Participants With Alcohol Use Disorder (PHASE2)
- A Clinical Trial Evaluating the Monkeypox Recombinant Protein Vaccine (PHASE1)
- Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity (PHASE3)
- Probiotic Intervention Study (NA)
- Multicenter Study to Assess the Efficacy and Safety of LB-102 in the Treatment of Adult Patients With BP1MDE. (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |